1-3 of 3
Zsolt Szabo, MD
Close
Sort by
Journal Articles

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lucy DeCosta, MSc, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Zsolt Szabo, MD, Xavier Leleu, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3120.
https://doi.org/10.1182/blood.V130.Suppl_1.3120.3120
Published: 2017
Journal Articles

Exploration of Survival Stratification of Patients with Multiple Myeloma after First Relapse Using Real World Data

Roman Hájek, Jiri Jarkovsky, MSc, PhD, Walter Bouwmeester, Maarten Treur, Lucy DeCosta, Marco Campioni, Michel Delforge, Marc S. Raab, MD, Paul Schoen, Zsolt Szabo, MD, Brozova Lucie, Sebastian Gonzalez-McQuire
Journal: Blood
Blood (2016) 128 (22): 2417.
https://doi.org/10.1182/blood.V128.22.2417.2417
Published: 2016
Journal Articles

The Value of Risk Stratification Tools in Multiple Myeloma (MM) in the Real-World: Validation of the Revised- International Staging System (R-ISS) at Initiation of Treatment and Relevance of the ISS and the R-ISS for Risk Stratification in the Relapsed Setting Using Data from the Czech Registry of Monoclonal Gammopathies (RMG)

Roman Hájek, Jiri Jarkovsky, MSc, PhD, Walter Bouwmeester, Maarten Treur, DeCosta Lucy, Marco Campioni, Michel Delforge, Marc S. Raab, MD, Paul Schoen, Zsolt Szabo, MD, Sebastian Gonzalez-McQuire
Journal: Blood
Blood (2016) 128 (22): 2418.
https://doi.org/10.1182/blood.V128.22.2418.2418
Published: 2016